Lilly Navigates GLP-1 Coverage Cuts with Part D Bridge, Acquires LimmaTech for $780M
LLY sits 82% above its 52-week low of $623.78.
Summary
Employers are planning to drop GLP-1 coverage in 2027, posing a future challenge for Eli Lilly's key weight-loss drugs like Foundayo and Zepbound. To counter this, Lilly is launching a GLP-1 Bridge Program for Medicare Part D patients, offering a $50 monthly copay from July 2026 through 2027. This strategic move aims to maintain patient access and sales amidst potential market shifts. Separately, Lilly acquired Swiss biotech LimmaTech for up to $780 million, adding a Phase 1 Staphylococcus aureus vaccine candidate to its early-stage pipeline. This acquisition follows other recent M&A activity, including a $6.3 billion deal for Centessa assets earlier this year. The long-term impact of employer coverage changes on GLP-1 demand will be critical to monitor.
At the time of this announcement, LLY was trading at $1,133.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.